Alliance Pharma Share Discussion Threads

[dround87] 11/2/2019 14:25

With 400k in the red? Doubt it.

[rathean] 11/2/2019 11:25

Up against the fence again this morning, one foot north of 70 and we could see mid-80s quickly imo dyor ofc.

[wetdream] 11/2/2019 09:27

Looks like someone's keen for this to stay below 70p.

[dround87] 08/2/2019 13:23

Great to see some volume and appetite for buying around 70p. Confidence is finally being shown at the higher price point even after the market stumble yesterday. Praying for a blue day in the US and we might even see another surge across the board early next week. Just don't say the B word!

[dround87] 06/2/2019 16:16

Ah yes that well know technical term "give it a shove!"

[rathean] 06/2/2019 15:20

Damn your technical analysis, leave me to my W fantasies :)

[dround87] 06/2/2019 13:31

Just needs a good shove over 70 now and I reckon we have some legs. Come on! Still losses from Shocktober recovered. Portfolio at an all time high. Having a good day!

[pleaty1] 06/2/2019 09:37

Looks like my youngest's spelling book. Practicing W's

[dround87] 06/2/2019 09:36

Oof! That 300k will balance the books! Good timing.

[dround87] 06/2/2019 07:10

I've said it again and again. Look at the aim chart and you won't be so confused. Same pattern. Same timing.

[dround87] 06/2/2019 07:08

That's why I didn't sell it all! Been sat in the doldrums too long and because I've averaged down to 63p I was over exposed. Just glad to finally turn a decent profit.

[2vdm] 05/2/2019 20:40

Sound move if you are a trader. Personally I think this is a long play and I just keep adding on the dips. Like the management, like the product, profitability and cash generation. Maybe won't set the world on fire, ticks all my boxes as a LTH.

[dround87] 05/2/2019 17:48

Predictable. Not enough support to keep going. Top sliced half my stake at 68. Bigger fish to fry!

[dround87] 05/2/2019 14:44

Let's call it a double bottom and make ourselves feel better!

[dogwalker] 05/2/2019 14:10

It's a ziggy-zaggy uppie-downie thing, surely.

[rathean] 05/2/2019 11:32

Is that a W I see before me or am I seeing things :)

[dround87] 05/2/2019 10:55

Good stuff! Obviously plenty of appetite for selling here but that's a good rise. I'll maybe put a loose stop in now to protect some profit just in case selling pressure ramps up.

[sunny_singh1] 04/2/2019 16:05

Revealed: UK patients stockpile drugs in fear of no-deal Brexit

[marksp2011] 04/2/2019 13:11

Wet

The Normal market Size for APH is 20k shares.
All trades below that need to be reported in a timely manner. Above 20K and they can delay the announcement

There are a slew of deferred publication rules that allow this not to happen

large Sizes relative to the NMS
the nature of the counterparties
reasons for the trade etc etc etc

A trade for a million could have taken a month or more to go through the market so you have no idea from the ADVFN reporting whether it was a buy/sell

[dround87] 01/2/2019 15:40

Not a chartist personally but sometimes you have to acknowledge that a lot of trades are based on technical analysis. A move up from here would break us out of the descending wedge we've been stuck in. Markets are supportive for now with the FTSE cracking 7k. Need some blue volume on the trading screen next week to make it stick though. Fingers crossed!

[wetdream] 31/1/2019 02:15

Apologies. Bit out of sync as in Sydney....
Was previous day 29th. 3m sold around 3pm; 1.7m traded aroubd close.
May not be 'massive' to some here, but plenty more than I hold!

[dround87] 30/1/2019 20:07

Looks like a big gamble. The future of FARN seems to be hanging on the result after they racked up a massive loss in research costs. Good luck with it though.

[bioking] 30/1/2019 15:17

FARN explodingggggggggggggggg

Faron Pharma (FARN) = Market cap 17 million / YODA Results & Final Phase 3 results from Japan IMMINENT / Traumakine as orhpan Drug has over $500 million in sales potential / NO approved Drug to date for the treatment of ARDS = 1000% UPSIDE Potential easily


The YODA study will now examine concomitant administration of prednisolone and Traumakine in order to confirm, in vivo, the observed interference of corticosteroids on IFN-beta bioactivity in the INTEREST study and ex vivo lung samples. These YODA results are expected during Q1 2019.

The company continues to await top-line data from the Phase III ARDS trial with Japanese partner Maruishi (JapicCTI-163320) to help determine next steps for Traumakine's development. These data, originally expected before the end of year, are now anticipated by Faron in early 2019.


Faron Pharma confident Traumakine could be ‘very effective’ for ARDS subgroup
[...]

Faron Pharma (LON:FARN) CEO Markku Jalkanen tells Proactive London’s Andrew Scott he's confident their Traumakine drug has the potential to treat around a third of acute respiratory distress syndrome (ARDS) patients in Europe and North America

ARDS is a life-threatening ailment caused by an inflammation of the lungs that usually coincides with illnesses such as pneumonia or severe flu.

Following on from a phase III trial of Traumakine earlier this year scientists have discovered that patients with a particular type of genetic mutation - called a C/T mutation - were almost six times more likely to survive than those who were also taking the drug but didn’t have the mutation

Faron will now liaise with European and US regulators to figure out the next best step for the drug.

[2vdm] 30/1/2019 15:14

what massive trades ?!